Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 186

1.

High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.

Schulkind J, Stephens B, Ahmad F, Johnston L, Hutchinson S, Thain D, Ward Z, Vickerman P, Hickman M, Dillon JF.

J Viral Hepat. 2018 Nov 13. doi: 10.1111/jvh.13035. [Epub ahead of print]

PMID:
30422370
2.

Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.

Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, Trickey A, Abbott S, Strathdee SA, Abramovitz D, Maher L, Iversen J, Bruneau J, Zang G, Garfein RS, Yen YF, Azim T, Mehta SH, Milloy MJ, Hellard ME, Sacks-Davis R, Dietze PM, Aitken C, Aladashvili M, Tsertsvadze T, Mravčík V, Alary M, Roy E, Smyrnov P, Sazonova Y, Young AM, Havens JR, Hope VD, Desai M, Heinsbroek E, Hutchinson SJ, Palmateer NE, McAuley A, Platt L, Martin NK, Altice FL, Hickman M, Vickerman P.

Lancet Infect Dis. 2018 Oct 29. pii: S1473-3099(18)30469-9. doi: 10.1016/S1473-3099(18)30469-9. [Epub ahead of print]

3.

Usage of low dead space syringes and association with hepatitis C prevalence amongst people who inject drugs in the UK.

Trickey A, May MT, Hope V, Ward Z, Desai M, Heinsbroek E, Hickman M, Vickerman P.

Drug Alcohol Depend. 2018 Nov 1;192:118-124. doi: 10.1016/j.drugalcdep.2018.07.041. Epub 2018 Sep 15.

PMID:
30245460
4.

A mechanistic hydro-epidemiological model of liver fluke risk.

Beltrame L, Dunne T, Vineer HR, Walker JG, Morgan ER, Vickerman P, McCann CM, Williams DJL, Wagener T.

J R Soc Interface. 2018 Aug;15(145). pii: 20180072. doi: 10.1098/rsif.2018.0072.

5.

Crowdsourcing to expand HIV testing among men who have sex with men in China: A closed cohort stepped wedge cluster randomized controlled trial.

Tang W, Wei C, Cao B, Wu D, Li KT, Lu H, Ma W, Kang D, Li H, Liao M, Mollan KR, Hudgens MG, Liu C, Huang W, Liu A, Zhang Y, Smith MK, Mitchell KM, Ong JJ, Fu H, Vickerman P, Yang L, Wang C, Zheng H, Yang B, Tucker JD.

PLoS Med. 2018 Aug 28;15(8):e1002645. doi: 10.1371/journal.pmed.1002645. eCollection 2018 Aug.

6.

The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study.

Borquez A, Beletsky L, Nosyk B, Strathdee SA, Madrazo A, Abramovitz D, Rafful C, Morales M, Cepeda J, Panagiotoglou D, Krebs E, Vickerman P, Claude Boily M, Thomson N, Martin NK.

Lancet Public Health. 2018 Sep;3(9):e429-e437. doi: 10.1016/S2468-2667(18)30097-5. Epub 2018 Aug 17.

7.

The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey.

Sood A, Suryaprasad A, Trickey A, Kanchi S, Midha V, Foster MA, Bennett E, Kamili S, Alvarez-Bognar F, Shadaker S, Surlikar V, Garg R, Mittal P, Sharma S, May MT, Vickerman P, Averhoff F.

PLoS One. 2018 Jul 26;13(7):e0200461. doi: 10.1371/journal.pone.0200461. eCollection 2018.

8.

Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs.

Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, Vickerman P, Blach S, Cunningham EB, Dumchev K, Lynskey M, Stone J, Trickey A, Razavi H, Mattick RP, Farrell M, Dore GJ, Degenhardt L.

Addiction. 2018 Jul 23. doi: 10.1111/add.14393. [Epub ahead of print]

PMID:
30035835
9.

Estimating the contribution of key populations towards the spread of HIV in Dakar, Senegal.

Mukandavire C, Walker J, Schwartz S, Boily MC, Danon L, Lyons C, Diouf D, Liestman B, Diouf NL, Drame F, Coly K, Muhire RSM, Thiam S, Diallo PAN, Kane CT, Ndour C, Volz E, Mishra S, Baral S, Vickerman P.

J Int AIDS Soc. 2018 Jul;21 Suppl 5:e25126. doi: 10.1002/jia2.25126.

10.

Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study.

Cepeda JA, Eritsyan K, Vickerman P, Lyubimova A, Shegay M, Odinokova V, Beletsky L, Borquez A, Hickman M, Beyrer C, Martin NK.

Lancet HIV. 2018 Oct;5(10):e578-e587. doi: 10.1016/S2352-3018(18)30168-1. Epub 2018 Jul 20.

PMID:
30033374
11.

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.

Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C.

Lancet. 2018 Jul 28;392(10144):312-358. doi: 10.1016/S0140-6736(18)31070-5. Epub 2018 Jul 20. Review. No abstract available.

PMID:
30032975
12.

The effect of HIV prevention products on incentives to supply condomless commercial sex among female sex workers in South Africa.

Quaife M, Vickerman P, Manian S, Eakle R, Cabrera-Escobar MA, Delany-Moretlwe S, Terris-Prestholt F.

Health Econ. 2018 Oct;27(10):1550-1566. doi: 10.1002/hec.3784. Epub 2018 Jun 21.

13.

Integrated Hepatitis C Care for People Who Inject Drugs (Heplink): Protocol for a Feasibility Study in Primary Care.

McCombe G, Swan D, O'Connor E, Avramovic G, Vickerman P, Ward Z, Surey J, Macías J, Lambert JS, Cullen W.

JMIR Res Protoc. 2018 Jun 4;7(6):e149. doi: 10.2196/resprot.9043.

14.

Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence.

Kouyoumjian SP, Heijnen M, Chaabna K, Mumtaz GR, Omori R, Vickerman P, Abu-Raddad LJ.

AIDS. 2018 Jun 19;32(10):1343-1352. doi: 10.1097/QAD.0000000000001828.

15.

Cost of provision of opioid substitution therapy provision in Tijuana, Mexico.

Burgos JL, Cepeda JA, Kahn JG, Mittal ML, Meza E, Lazos RRP, Vargas PC, Vickerman P, Strathdee SA, Martin NK.

Harm Reduct J. 2018 May 23;15(1):28. doi: 10.1186/s12954-018-0234-x.

16.

Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.

Fraser H, Mukandavire C, Martin NK, Goldberg D, Palmateer N, Munro A, Taylor A, Hickman M, Hutchinson S, Vickerman P.

Addiction. 2018 Nov;113(11):2118-2131. doi: 10.1111/add.14267. Epub 2018 Jul 10.

PMID:
29781207
17.

Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets?

Ward Z, Platt L, Sweeney S, Hope VD, Maher L, Hutchinson S, Palmateer N, Smith J, Craine N, Taylor A, Martin N, Ayres R, Dillon J, Hickman M, Vickerman P.

Addiction. 2018 May 17. doi: 10.1111/add.14217. [Epub ahead of print]

18.

The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom.

Hickman M, Steer C, Tilling K, Lim AG, Marsden J, Millar T, Strang J, Telfer M, Vickerman P, Macleod J.

Addiction. 2018 Aug;113(8):1461-1476. doi: 10.1111/add.14188. Epub 2018 Apr 19.

PMID:
29672985
19.

The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.

Quaife M, Terris-Prestholt F, Eakle R, Cabrera Escobar MA, Kilbourne-Brook M, Mvundura M, Meyer-Rath G, Delany-Moretlwe S, Vickerman P.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25064.

20.

How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity.

Quaife M, Terris-Prestholt F, Di Tanna GL, Vickerman P.

Eur J Health Econ. 2018 Nov;19(8):1053-1066. doi: 10.1007/s10198-018-0954-6. Epub 2018 Jan 29.

Supplemental Content

Loading ...
Support Center